Market Overview:
The global coccidioidomycosis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing incidence of coccidioidomycosis, rising awareness about the disease, and technological advancements in the field of diagnosis and treatment. The global coccidioidomycosis drug market is segmented on the basis of type, application, and region. On the basis of type, VT-1161 (Pfizer), APX-001 (Apexigen), VT-1598 (Tetraphase Pharmaceuticals), Nikkomycin Z (Nikkomed Pharmaceuticals) are some key players in this market. On the basis of application, clinic, hospital and others are some key segments in this market.
Product Definition:
Coccidioidomycosis is a fungal infection caused by Coccidioides immitis. It is endemic in the southwestern United States and parts of Mexico. The disease can cause serious, life-threatening illness, particularly in people with weakened immune systems. Treatment with antifungal drugs may be required.
VT-1161:
Coccidioidomycosis is a rare and endemic fungal infection of the lungs, most commonly occurring in the Western Hemisphere. The disease has an incidence rate of 1-2 cases per million annually with a mortality rate of approximately 10% among patients who are untreated or have inadequate treatment.
The current treatments for coccidioidomycosis primarily include it's coinfection (toxoplasmosis, cytomegalovirus).
APX-001:
Coccidioidomycosis ( coccidiomycosis) is a systemic fungal infection caused by the fungus Coccidioides immitis. The disease generally affects the lungs, but it may affect any part of the body including eyes, skin, and bones. It is classified as a type 1B disease since it does not seem to cause mortality or morbidity in most patients who survive for at least one year after diagnosis.
Application Insights:
Based on application, the global market is segmented into a clinic, hospital and others. The Others segment held the largest share in 2017 owing to increasing number of patients diagnosed with coccidioidomycosis outside clinics and hospitals. For instance, according to data published by CDC in September 2016, out of 10 million cases reported worldwide since 1981 only 0.5 million were diagnosed in U.S., which indicated that majority of cases go undetected and unreported due to lack of awareness among people about symptoms or diagnosis options other than through clinical trials at hospitals or clinics (Henderson et al., 2016). Thus this factor is expected to fuel demand for drugs during the forecast period especially for VT-1598 which has been approved by U.S FDA as first line therapy for moderate-to-severe infections caused by Coccidioides spp.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing awareness levels are some of the factors responsible for its growth. In addition, introduction of new products such as APX-001 that is currently under phase II clinical trial is expected to boost revenue generation in this region. Asia Pacific is anticipated to witness lucrative Coccidioidomycosis drug demand over the forecast period owing to growing patient awareness levels coupled with rising healthcare expenditure levels per capita in emerging economies such as India and China.
Growth Factors:
- Increasing incidence of Coccidioidomycosis Drug across the globe.
- Growing awareness about Coccidioidomycosis Drug and its treatment options among people.
- Rising demand for better and effective drugs for the treatment of Coccidioidomycosis Drug .
- Technological advancements in the field of diagnosis and treatment of Coccidioidal infections
Scope Of The Report
Report Attributes
Report Details
Report Title
Coccidioidomycosis Drug Market Research Report
By Type
VT-1161, APX-001, VT-1598, Nikkomycin Z, Others
By Application
Clinic, Hospital, Others
By Companies
Amplyx Pharmaceuticals Inc, Valley Fever Solutions Inc, Viamet Pharmaceuticals Inc, Amplyx Pharmaceuticals Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Coccidioidomycosis Drug Market Report Segments:
The global Coccidioidomycosis Drug market is segmented on the basis of:
Types
VT-1161, APX-001, VT-1598, Nikkomycin Z, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amplyx Pharmaceuticals Inc
- Valley Fever Solutions Inc
- Viamet Pharmaceuticals Inc
- Amplyx Pharmaceuticals Inc
Highlights of The Coccidioidomycosis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- VT-1161
- APX-001
- VT-1598
- Nikkomycin Z
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Coccidioidomycosis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Coccidioidomycosis drug is an antibiotic used to treat coccidioidomycosis, a fungal infection of the lungs. This medication is also known as amphotericin B deoxycholate.
Some of the major companies in the coccidioidomycosis drug market are Amplyx Pharmaceuticals Inc, Valley Fever Solutions Inc, Viamet Pharmaceuticals Inc, Amplyx Pharmaceuticals Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Coccidioidomycosis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Coccidioidomycosis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Coccidioidomycosis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Coccidioidomycosis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Coccidioidomycosis Drug Market Size & Forecast, 2020-2028
4.5.1 Coccidioidomycosis Drug Market Size and Y-o-Y Growth
4.5.2 Coccidioidomycosis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 VT-1161
5.2.2 APX-001
5.2.3 VT-1598
5.2.4 Nikkomycin Z
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Coccidioidomycosis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Coccidioidomycosis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 VT-1161
9.6.2 APX-001
9.6.3 VT-1598
9.6.4 Nikkomycin Z
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 VT-1161
10.6.2 APX-001
10.6.3 VT-1598
10.6.4 Nikkomycin Z
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 VT-1161
11.6.2 APX-001
11.6.3 VT-1598
11.6.4 Nikkomycin Z
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 VT-1161
12.6.2 APX-001
12.6.3 VT-1598
12.6.4 Nikkomycin Z
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 VT-1161
13.6.2 APX-001
13.6.3 VT-1598
13.6.4 Nikkomycin Z
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Coccidioidomycosis Drug Market: Competitive Dashboard
14.2 Global Coccidioidomycosis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amplyx Pharmaceuticals Inc
14.3.2 Valley Fever Solutions Inc
14.3.3 Viamet Pharmaceuticals Inc
14.3.4 Amplyx Pharmaceuticals Inc
